Response to: 'Correspondence to: 'Combination of human umbilical cord mesenchymal stem cell transplantation with IFN- γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis' by Ma *et al*

We thank Ma *et al*¹ for their interest in our recent report titled 'Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN- γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'.² Ma *et al*¹ brought up an important issue regarding the safety profile of intramuscular infusion of interferon (IFN)- γ , which may initiate further immune reactions.^{3,4} As previously described, recombinant human IFN- γ monotherapy is known to be safe but ineffective in treating rheumatoid arthritis.^{5,6} Furthermore, the safety of IFN- γ -primed mesenchymal stem (stromal) cells (MSCs) remains unknown, as there has been no such clinical research report addressing this issue. Therefore, for the subject's maximum safety considerations, the clinical protocol was MSC transplantation (MSCT) plus intramuscular infusion of IFN- γ , instead of IFN- γ -primed MSCs, and as we have anticipated no new or unexpected safety issues were reported for either treatment group for up to 1 year. Indeed, in future studies, interpreting the safety of the IFN- γ -primed MSC protocols would be more appropriate than that of recombinant IFN- γ monotherapy from a translational standpoint.

As to the question of whether MSCT plus intramuscular infusion of IFN- γ would further modulate serum levels of IFN- γ in patients, all patients who received intramuscular infusion of IFN- γ had a transient increase in serum IFN- γ level within 24 hours after infusion, which gradually decreased during the subsequent follow-up. However, as we described in our previous study that there are huge individual variations in the baseline serum IFN- γ levels,⁷ we did not list the IFN- γ data. In addition, with regard to the serum level of proinflammatory cytokines, consistent with our previous study,⁷ there was a significant decrease in the serum levels of tumour necrosis factor- α and interleukin (IL)-6 among patients of the MSCT plus IFN- γ group, while no significant changes in IL-1 β , IL-2R and IL-8 levels were observed. Unfortunately, we did not find that such a proinflammatory cytokine combination affected the immunosuppressive functions of MSCs, as observed in the *in vitro* study.

Finally, we agreed that it is possible that the flow cytometry (FC) gauged percentages of CD3+ and IFN- γ + MSCs could differ using different control techniques for gating. In our study, isotype controls were used for identification of the background binding caused by antibody isotypes. As there are only two kinds of fluorochromes involved in the FC experiment, a single positive control technique was more adequate as a compensation control technique than the fluorescence minus one control technique, which is suitable for multiple fluorochromes (≥ 3) FC study.^{8,9}

Yi Yang,¹ Xiao He,^{1,2} Mengwei Yao,¹ Wei Xing,¹ Luoquan Ao,¹ Joseph A Bellanti,^{3,4} Song Guo Zheng ,⁵ Xiang Xu

¹Department of Stem Cell and Regenerative Medicine of Daping Hospital, Army Medical University, Chongqing, China

²Emergency Department, PLA Rocket Force Characteristic Medical Center, Beijing, China

³Departments of Pediatrics and Microbiology-Immunology, Georgetown University Medical Center, Washington, DC, USA

⁴Georgetown University, Washington, DC, USA

⁵Division of Rheumatology, Department of Internal Medicine, Ohio State University college of Medicine and Wexner Medical center, Columbus, Ohio, USA

Correspondence to Dr Xiang Xu, Department of Stem Cell & Regenerative Medicine of Daping Hospital, Army Medical University, Chongqing 400042, China; xiangxu@tmmu.edu.cn

Handling editor Josef S Smolen

Contributors YY, XH, MY, WX and LA wrote the original draft of the manuscript. JAB, SGZ and XX reviewed and edited the manuscript. XX acquired funding and supervised the study.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Yang Y, He X, Yao M, *et al*. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2020-218762

Received 5 August 2020

Revised 10 August 2020

Accepted 12 August 2020

► <http://dx.doi.org/10.1136/annrheumdis-2020-218704>

Ann Rheum Dis 2020;**0**:1. doi:10.1136/annrheumdis-2020-218762

ORCID iDs

Song Guo Zheng <http://orcid.org/0000-0002-5611-4774>

Xiang Xu <http://orcid.org/0000-0002-1026-2210>

REFERENCES

- Kevin Sheng-Kai MA, Wang L-T, Tsai S-Y. 'Combination of human umbilical cord mesenchymal stem cell transplantation with IFN- γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'. *Ann Rheum Dis* 2020;annrheumdis-2020-218704.
- He X, Yang Y, Yao M, *et al*. Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN- γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis. *Ann Rheum Dis* 2020. doi:10.1136/annrheumdis-2020-217798. [Epub ahead of print: 19 Jun 2020].
- Hu X, Ivashkiv LB. Cross-Regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. *Immunity* 2009;31:539–50.
- Zaidi MR, Merlino G. The two faces of interferon- γ in cancer. *Clin Cancer Res* 2011;17:6118–24.
- Veys EM, Menkes CJ, Emery P, A randomized EP. A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis. *Arthritis Rheum* 1997;40:62–8.
- Cannon GW, Pincus SH, Emkey RD, *et al*. Double-Blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. *Arthritis Rheum* 1989;32:964–73.
- Yang Y, He X, Zhao R, *et al*. Serum IFN- γ levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis. *J Transl Med* 2018;16:165.
- Feher K, Kirsch J, Radbruch A, *et al*. Cell population identification using fluorescence-minus-one controls with a one-class classifying algorithm. *Bioinformatics* 2014;30:3372–8.
- Maecker HT, Trotter J. Flow cytometry controls, instrument setup, and the determination of positivity. *Cytometry A* 2006;69:1037–42.